MT-2 | 10 vials

MT-2 (Melanotan II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), engineered to be significantly more potent than its linear predecessor . It was developed at the University of Arizona in the 1990s as part of research into melanocortin receptor agonists .

Key Specifications:

• CAS Number: 121062-08-6

• Molecular Formula: C₅₀H₆₉N₁₅O₉

• Molecular Weight: ~1024 Da

• UNII: UPF5CJ93X7

• Synonyms: MT-II, Melanotan II, [Nle⁴-D-Phe⁷]-α-MSH (cyclic lactam version)

• Purity: Variable (unregulated market; research grade typically ≥95-98%)

• Appearance: White lyophilized powder

• Storage: Store at 2-8°C (refrigerated); protect from light

Mechanism of Action:

MT-2 acts as a non-selective melanocortin receptor agonist, binding to multiple receptor subtypes :

• MC1R (melanocortin-1 receptor): Located on melanocytes—stimulates eumelanin production, resulting in skin darkening independent of UV exposure

• MC3R/MC4R (melanocortin-3 and -4 receptors): Located in the central nervous system—modulate appetite, energy homeostasis, and sexual function

The cyclic structure of MT-2 improves stability and potency, allowing lower doses to exert strong effects, but this comes with broader ("pharmacologically noisy") receptor activity .

Research Applications:

Clinical History:

MT-2 was investigated clinically for erectile dysfunction and showed promise, with Phase I/II trials completed . However, development stalled due to side effects (primarily nausea), and the program was ultimately not commercialized . A derivative, PT-141 (bremelanotide) , was developed from MT-2 and is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women .

Important Notice:

FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS.